#multitumor

[firstmedicaldiagnosticspvtltd]

We aim to Prevent You From Falling Sick At An Early Stage | FMD

When an astrologer predicts future events for you, the sense of excitement and amazement is undeniable, isn't it? It's an experience that captivates and intrigues, offering a glimpse into the possibilities that lie ahead. When both positive and negative factors that could impact your life are known beforehand, you are better equipped to make informed decisions. 

But what can happen when you know the future of your health? Knowing the future of your health empowers you to proactively make the right decision that positively influences your overall well-being. It allows you to adopt preventive measures, make lifestyle adjustments, and prioritize self-care, ultimately steering you toward a healthier and more fulfilling life. By gaining insights into potential health outcomes, you make rational decisions and actively take part in shaping a future where your well-being is your priority.

How First Medical Diagnostics Empowers Early Detection

At First Medical Diagnostics, we're more than just a healthcare provider; we're your partners in well-being. We understand that staying healthy isn't just about reacting to illness – it's about being proactive, taking charge, and living your best life. Our mission is deeply rooted in this philosophy. We're not only here to diagnose diseases and symptoms but to be your true companion in prevention.

Imagine a healthcare experience where we work together to identify potential health issues in their earliest stages. It's like having a personalized early warning system for your well-being. By catching concerns before they have a chance to disrupt your life, we empower you to stay in control and live each day to the fullest.

Why Early Detection Matters?

Early detection is a game-changer in healthcare. It can significantly improve patient outcomes and increase the chances of successful treatment. By identifying diseases or conditions at a primary stage, healthcare professionals can intervene sooner and implement preventive measures. It can also lead to cost savings, as treating a disease in its early stages is often less expensive than treating it in its advanced stages.

Early detection of a health problem leads to prompt intervention, often with less invasive and more effective options. This can result in better health outcomes and a higher chance of successful treatment. For example, if a person notices early symptoms of cancer and seeks medical attention, they may be able to receive targeted therapy or surgery, which can be less invasive than later-stage treatments like chemotherapy. For this, we offer a PanTum Test that helps in the early detection of cancer cells and prevents you from suffering in the future.

Better treatment results: There is a substantial increase in the chance of a full recovery and a successful course of treatment with early intervention. Early intervention allows for the identification and management of health conditions at their early stages, when they are most treatable. By detecting and addressing problems early on, medical professionals can prevent the progression of diseases and minimize potential complications.

Reduced burden on healthcare systems: By preventing serious illnesses, we alleviate the strain on hospitals and resources, benefiting everyone. This reduction in burden allows healthcare systems to allocate their resources more efficiently, ensuring that those who truly need medical attention receive it promptly. It also helps in decreasing waiting times for treatments and surgeries, improving overall patient care.

Specialized Tests, Powered by German Expertise:

Our specialized tests bring you the latest in German expertise, ensuring accuracy and reliability. We don't stop at just offering test results instead our group of medical specialists will assist you at every turn, providing:

Professional interpretation of your test results: We'll discuss the significance of your test results and how they may affect your health.

Personalized consultations: After talking about your lifestyle and risk factors, we'll create a strategy specifically for controlling your health and lowering your chance of getting sick in the future.

After the initial consultation, we're here to help with ongoing support and monitoring. We'll make any necessary changes to your plan and still provide ongoing monitoring.

Investing in Your Future Well-Being

Investing in early detection is a future-oriented investment. It's about assuming responsibility for your health and giving yourself the tools you need to live a longer, better life. First Medical Diagnostics is dedicated to giving you the resources required to do this.

We believe that everyone should have access to state-of-the-art medical treatment and individualized diagnostics. For this reason, we provide customizable testing plans and alternatives to fit your requirements and price range.

For more information,

Call us at +91 8800929600

Visit us at www.fmdindia.in

[cancersfakianakis1]

Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders

The neurofibromatoses consist of at least three autosomal-dominant inherited disorders: neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. For over 80 years, these conditions were inextricably tied together under generalized neurofibromatosis. In 1987, the localization of NF1 to chromosome 17q and NF2 (bilateral vestibular schwannoma) to 22q led to a consensus conference at Bethesda, Maryland. The two main neurofibromatoses, NF1 and NF2, were formally separated. More recently, the SMARCB1 and LZTR1 genes on 22q have been confirmed as causing a subset of schwannomatosis. The last 26 years have seen a great improvement in understanding of the clinical and molecular features of these conditions as well as insights into management. Childhood presentation of NF2 (often with meningioma) in particular predicts a severe multitumor disease course. Malignancy is rare in NF2, particularly in childhood; however, there are substantial risks from benign and low-grade central nervous system (CNS) tumors necessitating MRI surveillance to optimize management. At least annual brain MRI, including high-resolution images through the auditory meatus, and a clinical examination and auditory assessment are required from diagnosis or from around 10 to 12 years of age if asymptomatic. Spinal imaging at baseline and every 2 to 3 years is advised with more frequent imaging if warranted on the basis of sites of tumor involvement. The malignancy risk in schwannomatosis is not well defined but may include an increased risk of malignant peripheral nerve sheath tumor in SMARCB1. Imaging protocols are also proposed for SMARCB1 and LZTR1 schwannomatosis and SMARCE1-related meningioma predisposition. Clin Cancer Res; 23(12); e54–e61. ©2017 AACR.

See all articles in the online-only CCR Pediatric Oncology Series.

http://ift.tt/2toRb5P

[healthy-insights]

Tissue Microarray Industry 2024 Market Research Report: Growth & Forecast To 2022 Including Key Vendors

Tissue microarray is a high-throughput technology which accelerates and facilitates in situ analysis of tissue. The identification of disease causing gene is a major focus in the current advanced biomedical research. Array-based technology provides platform for molecular profiling of disease genes and tissue such as DNA array and tissue array. Thousands of genes are already identified using microarray technology that may be associated with disease initiation, development, and progression. The identification theses genes has enhanced the process of lead discovery. Clinical evaluation of such leads is a challenging task as it involves analysis of numerous well-characterized tissue specimens. Tissue microarray helps in the analysis of thousands of tissue samples simultaneously in using array format. The technique of tissue microarray helps to maintain the pace with lead discovery process.

Get Sample Copy of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20849

The tissue microarray technology involves core needle biopsies of numerous tissue constructed on the block. It is prepared from paraffin-embedded tissue, fresh tissue, or from archival formalin fixed tissue. Small size tissue cylinders of about 0.6 mm size are extracted from different primary tumor blocks (donor blocks) and are assembled in array format in single empty block (recipient blocks).Tissue microarray blocks are used simultaneously for in situ analysis of tissue samples. Tissue microarray can be manufactured manually or automatically.

Tissue microarray has a number of advantages over standard conventional techniques. Tissue microarray enables high throughput data acquisition with simultaneous analysis of large number of specimens. This technology allows analysis of samples in one batch on one slide, thus maintaining the uniformity of variables such as temperature, incubation period, washing interval, and antigen retrieval. The technique uses small amount of reagent and has proven to be highly effective and extremely efficient with short duration process. The technique retains the original block for diagnosis and conserves the crucial tissue of donors. The technique is widely used in the diagnosis of tumor, especially breast cancer and lung cancer. In addition, tissue microarray is used for identification of novel molecular marker and clinical validation of new genes on histopathological platform for meaningful outcome. Tissue microarray is categorized into three types: multitumor array used for screening large group of tumor for presence and absence of marker; tumor progression array used for studying of molecular and morphological variation at different stage of tumor progression; prognostic array for studying the correlation of clinical follow up outcome with microarray data. Factors such as increase in number of cases of tumor patient along with technology advances and adoption of microarray technique in genomic and proteomic filed due its rapid assay, uniformity in result, fewer sample requirement are anticipated to augment the growth of the tissue microarray market. However, high cost of microarray techniques and preference of users for alternative techniques such as PCR are projected to restrain the market growth during the forecast period.

The global market for tissue microarray has been segmented on the basis of product, application, end-user, and geography. On the basis of product, the market is segmented into cell line array, frozen tissue array, paraffin embedded tissue array, tissue array slides, and others. The paraffin embedded tissue array segment is estimated to dominate the market during the forecast period. On the basis of application, the market is classified into immunohistochemistry, FISH, mRNA, in situ hybridization, nucleic acid extraction, and others. The immunohistochemistry and in situ hybridization segments are anticipated to capture significant market shares in the near future due to increase in adoption of protein expression methodology for diagnosis of disease.

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others. The technique of tissue microarray is highly precise and requires skilled person to handle and analyze the output data. Thus the market for hospital is anticipated to witness high growth during the forecast period.

Based on geography, the market has been distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant market share and is projected to retain its dominance during the forecast period due to increase in health care expenditure, advance technology adoption, and rise in number of cases of cancer.

The key players operating in the tissue microarray market are Abcam plc, Asterand Bioscience, Auria Biopankki, Externautics, Novus Biologicals, LLC, OriGene Technologies Inc., Protein Biotechnologies Inc, PREMIER Biosoft, Pantomics Inc., and US Biomax Inc.

View Report @ http://www.transparencymarketresearch.com/tissue-microarray-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com

[healthy-insights]

Tissue Microarray (TMR) Market: Industry Insights, Outlook And Forecast Upto 2024

Tissue microarray is a high-throughput technology which accelerates and facilitates in situ analysis of tissue. The identification of disease causing gene is a major focus in the current advanced biomedical research. Array-based technology provides platform for molecular profiling of disease genes and tissue such as DNA array and tissue array. Thousands of genes are already identified using microarray technology that may be associated with disease initiation, development, and progression. The identification theses genes has enhanced the process of lead discovery. Clinical evaluation of such leads is a challenging task as it involves analysis of numerous well-characterized tissue specimens. Tissue microarray helps in the analysis of thousands of tissue samples simultaneously in using array format. The technique of tissue microarray helps to maintain the pace with lead discovery process.

Get Sample Copy of this Report @

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20849

The tissue microarray technology involves core needle biopsies of numerous tissue constructed on the block. It is prepared from paraffin-embedded tissue, fresh tissue, or from archival formalin fixed tissue. Small size tissue cylinders of about 0.6 mm size are extracted from different primary tumor blocks (donor blocks) and are assembled in array format in single empty block (recipient blocks).Tissue microarray blocks are used simultaneously for in situ analysis of tissue samples. Tissue microarray can be manufactured manually or automatically.

Tissue microarray has a number of advantages over standard conventional techniques. Tissue microarray enables high throughput data acquisition with simultaneous analysis of large number of specimens. This technology allows analysis of samples in one batch on one slide, thus maintaining the uniformity of variables such as temperature, incubation period, washing interval, and antigen retrieval. The technique uses small amount of reagent and has proven to be highly effective and extremely efficient with short duration process. The technique retains the original block for diagnosis and conserves the crucial tissue of donors. The technique is widely used in the diagnosis of tumor, especially breast cancer and lung cancer. In addition, tissue microarray is used for identification of novel molecular marker and clinical validation of new genes on histopathological platform for meaningful outcome. Tissue microarray is categorized into three types: multitumor array used for screening large group of tumor for presence and absence of marker; tumor progression array used for studying of molecular and morphological variation at different stage of tumor progression; prognostic array for studying the correlation of clinical follow up outcome with microarray data. Factors such as increase in number of cases of tumor patient along with technology advances and adoption of microarray technique in genomic and proteomic filed due its rapid assay, uniformity in result, fewer sample requirement are anticipated to augment the growth of the tissue microarray market. However, high cost of microarray techniques and preference of users for alternative techniques such as PCR are projected to restrain the market growth during the forecast period.

The global market for tissue microarray has been segmented on the basis of product, application, end-user, and geography. On the basis of product, the market is segmented into cell line array, frozen tissue array, paraffin embedded tissue array, tissue array slides, and others. The paraffin embedded tissue array segment is estimated to dominate the market during the forecast period. On the basis of application, the market is classified into immunohistochemistry, FISH, mRNA, in situ hybridization, nucleic acid extraction, and others. The immunohistochemistry and in situ hybridization segments are anticipated to capture significant market shares in the near future due to increase in adoption of protein expression methodology for diagnosis of disease.

View Report @ http://www.transparencymarketresearch.com/tissue-microarray-market.html

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others. The technique of tissue microarray is highly precise and requires skilled person to handle and analyze the output data. Thus the market for hospital is anticipated to witness high growth during the forecast period.

Based on geography, the market has been distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant market share and is projected to retain its dominance during the forecast period due to increase in health care expenditure, advance technology adoption, and rise in number of cases of cancer.

The key players operating in the tissue microarray market are Abcam plc, Asterand Bioscience, Auria Biopankki, Externautics, Novus Biologicals, LLC, OriGene Technologies Inc., Protein Biotechnologies Inc, PREMIER Biosoft, Pantomics Inc., and US Biomax Inc.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com

[healthy-insights]

Tissue Microarray (TMR) Market Research Report by Regional Analysis : Forecast 2024

Tissue microarray is a high-throughput technology which accelerates and facilitates in situ analysis of tissue. The identification of disease causing gene is a major focus in the current advanced biomedical research. Array-based technology provides platform for molecular profiling of disease genes and tissue such as DNA array and tissue array. Thousands of genes are already identified using microarray technology that may be associated with disease initiation, development, and progression. The identification theses genes has enhanced the process of lead discovery. Clinical evaluation of such leads is a challenging task as it involves analysis of numerous well-characterized tissue specimens. Tissue microarray helps in the analysis of thousands of tissue samples simultaneously in using array format. The technique of tissue microarray helps to maintain the pace with lead discovery process.

Download The Full Brouchre of Report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20849

The tissue microarray technology involves core needle biopsies of numerous tissue constructed on the block. It is prepared from paraffin-embedded tissue, fresh tissue, or from archival formalin fixed tissue. Small size tissue cylinders of about 0.6 mm size are extracted from different primary tumor blocks (donor blocks) and are assembled in array format in single empty block (recipient blocks).Tissue microarray blocks are used simultaneously for in situ analysis of tissue samples. Tissue microarray can be manufactured manually or automatically.

Tissue microarray has a number of advantages over standard conventional techniques. Tissue microarray enables high throughput data acquisition with simultaneous analysis of large number of specimens. This technology allows analysis of samples in one batch on one slide, thus maintaining the uniformity of variables such as temperature, incubation period, washing interval, and antigen retrieval. The technique uses small amount of reagent and has proven to be highly effective and extremely efficient with short duration process. The technique retains the original block for diagnosis and conserves the crucial tissue of donors. The technique is widely used in the diagnosis of tumor, especially breast cancer and lung cancer. In addition, tissue microarray is used for identification of novel molecular marker and clinical validation of new genes on histopathological platform for meaningful outcome. Tissue microarray is categorized into three types: multitumor array used for screening large group of tumor for presence and absence of marker; tumor progression array used for studying of molecular and morphological variation at different stage of tumor progression; prognostic array for studying the correlation of clinical follow up outcome with microarray data. Factors such as increase in number of cases of tumor patient along with technology advances and adoption of microarray technique in genomic and proteomic filed due its rapid assay, uniformity in result, fewer sample requirement are anticipated to augment the growth of the tissue microarray market. However, high cost of microarray techniques and preference of users for alternative techniques such as PCR are projected to restrain the market growth during the forecast period.

The global market for tissue microarray has been segmented on the basis of product, application, end-user, and geography. On the basis of product, the market is segmented into cell line array, frozen tissue array, paraffin embedded tissue array, tissue array slides, and others. The paraffin embedded tissue array segment is estimated to dominate the market during the forecast period. On the basis of application, the market is classified into immunohistochemistry, FISH, mRNA, in situ hybridization, nucleic acid extraction, and others. The immunohistochemistry and in situ hybridization segments are anticipated to capture significant market shares in the near future due to increase in adoption of protein expression methodology for diagnosis of disease.

Browse Global Strategic Business Report: http://www.transparencymarketresearch.com/tissue-microarray-market.html

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others. The technique of tissue microarray is highly precise and requires skilled person to handle and analyze the output data. Thus the market for hospital is anticipated to witness high growth during the forecast period.

Based on geography, the market has been distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant market share and is projected to retain its dominance during the forecast period due to increase in health care expenditure, advance technology adoption, and rise in number of cases of cancer.

The key players operating in the tissue microarray market are Abcam plc, Asterand Bioscience, Auria Biopankki, Externautics, Novus Biologicals, LLC, OriGene Technologies Inc., Protein Biotechnologies Inc, PREMIER Biosoft, Pantomics Inc., and US Biomax Inc.

About Us Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement. US Office Contact 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: www.transparencymarketresearch.com

[healthy-insights]

Tissue Microarray (TMR) Market: Evolving Market Trends & Dynamics 2024

Tissue microarray is a high-throughput technology which accelerates and facilitates in situ analysis of tissue. The identification of disease causing gene is a major focus in the current advanced biomedical research. Array-based technology provides platform for molecular profiling of disease genes and tissue such as DNA array and tissue array. Thousands of genes are already identified using microarray technology that may be associated with disease initiation, development, and progression. The identification theses genes has enhanced the process of lead discovery. Clinical evaluation of such leads is a challenging task as it involves analysis of numerous well-characterized tissue specimens. Tissue microarray helps in the analysis of thousands of tissue samples simultaneously in using array format. The technique of tissue microarray helps to maintain the pace with lead discovery process.

Download Exclusive Brochure of This Report :

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=20849

The tissue microarray technology involves core needle biopsies of numerous tissue constructed on the block. It is prepared from paraffin-embedded tissue, fresh tissue, or from archival formalin fixed tissue. Small size tissue cylinders of about 0.6 mm size are extracted from different primary tumor blocks (donor blocks) and are assembled in array format in single empty block (recipient blocks).Tissue microarray blocks are used simultaneously for in situ analysis of tissue samples. Tissue microarray can be manufactured manually or automatically.

Tissue microarray has a number of advantages over standard conventional techniques. Tissue microarray enables high throughput data acquisition with simultaneous analysis of large number of specimens. This technology allows analysis of samples in one batch on one slide, thus maintaining the uniformity of variables such as temperature, incubation period, washing interval, and antigen retrieval. The technique uses small amount of reagent and has proven to be highly effective and extremely efficient with short duration process. The technique retains the original block for diagnosis and conserves the crucial tissue of donors. The technique is widely used in the diagnosis of tumor, especially breast cancer and lung cancer. In addition, tissue microarray is used for identification of novel molecular marker and clinical validation of new genes on histopathological platform for meaningful outcome. Tissue microarray is categorized into three types: multitumor array used for screening large group of tumor for presence and absence of marker; tumor progression array used for studying of molecular and morphological variation at different stage of tumor progression; prognostic array for studying the correlation of clinical follow up outcome with microarray data. Factors such as increase in number of cases of tumor patient along with technology advances and adoption of microarray technique in genomic and proteomic filed due its rapid assay, uniformity in result, fewer sample requirement are anticipated to augment the growth of the tissue microarray market. However, high cost of microarray techniques and preference of users for alternative techniques such as PCR are projected to restrain the market growth during the forecast period.

The global market for tissue microarray has been segmented on the basis of product, application, end-user, and geography. On the basis of product, the market is segmented into cell line array, frozen tissue array, paraffin embedded tissue array, tissue array slides, and others. The paraffin embedded tissue array segment is estimated to dominate the market during the forecast period. On the basis of application, the market is classified into immunohistochemistry, FISH, mRNA, in situ hybridization, nucleic acid extraction, and others. The immunohistochemistry and in situ hybridization segments are anticipated to capture significant market shares in the near future due to increase in adoption of protein expression methodology for diagnosis of disease.

On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others. The technique of tissue microarray is highly precise and requires skilled person to handle and analyze the output data. Thus the market for hospital is anticipated to witness high growth during the forecast period.

Based on geography, the market has been distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America holds a significant market share and is projected to retain its dominance during the forecast period due to increase in health care expenditure, advance technology adoption, and rise in number of cases of cancer.

The key players operating in the tissue microarray market are Abcam plc, Asterand Bioscience, Auria Biopankki, Externautics, Novus Biologicals, LLC, OriGene Technologies Inc., Protein Biotechnologies Inc, PREMIER Biosoft, Pantomics Inc., and US Biomax Inc.

Browse Global Strategic Business Report:

http://www.transparencymarketresearch.com/tissue-microarray-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: www.transparencymarketresearch.com